Organization
Mesothelioma Applied Research Foundation
Type
Foundation
Link
LOI Due Date
11-21-2022
Brief Description
Who Can Apply:
- Investigators who have a doctoral-level degree and a full-time faculty position or equivalent at a college, university, medical school, or eligible not-for-profit research organization globally.
- Junior investigators with an interest in a carrier focus in mesothelioma are strongly encouraged to apply to this RFA. As part of their application, they should identify an established mesothelioma researcher as their mentor and provide a career development and mentorship plan in the context of their application.
Additional information to be included in the LOI:
- All applications need to focus on pleural and/or peritoneal mesothelioma and should address at least one of the 2022 Areas of Interest (listed below).
- All projects must be feasible within the timeline and budgetary constraints of the current LOI.
- All other funding, overlapping and/or supplemental funding, for the proposed project should be disclosed as part of the application.
Areas of Interest 2022 (not listed in order of priority):
- Novel therapies for mesothelioma for both pleural and peritoneal, especially targeted therapies, combination immunotherapy, cellular therapy, and virotherapy.
- Health-related quality of life assessment incorporating the social determinants of health (SDOH) specific to mesothelioma patient care, side effect management, mental health care impact on patient and/or caregiver outcomes, and other related topics.
- Novel strategies for screening and early detection.
- Novel strategies for risk assessment and prognosis stratification.
- Immune mediated complications of immunotherapy in mesothelioma (monitoring, early detection, and management).
- Improving personalization of therapies (gender and racial differences, targeted therapies, and predictive biomarkers).
- Mechanisms of treatment resistance/failure.
- Mesothelioma biology and etiology (disease-defining molecular pathways, cellular biology, and/or tumor microenvironment).